Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymetrix, Inc.
Affymetrix Announces New Cost-effective Product for Standardizing Drug Metabolism Studies
November 28th, 2008
Affymetrix, Inc. (Nasdaq:AFFX) announced the DMET(TM) Plus Premier Pack, the most comprehensive method for standardizing drug metabolism studies. The DMET (Drug Metabolism Enzymes and Transporters) Plus Panel features the most biologically relevant content identified by key opinion leaders from industry and academia in a cost-effective format. The DMET Plus Panel contains markers in all FDA-validated genes(1) and covers more than 90 percent of the current ADME Core markers as defined by the PharmaADME group. It offers 1,936 high-value drug metabolism and transporter markers. Researchers in the pharmacology of cancer therapies are already using the DMET Panel to better...
Source: Health Business Week (2008-11-28)
|
